A Phase III, Randomized, Partially Double-Blind and Placebo-Controlled Study of BI 207127 in Combination With Faldaprevir and Ribavirin in Treatment-Naive Patients With Chronic Genotype 1 HCV Infection
Phase of Trial: Phase III
Latest Information Update: 30 Jun 2017
At a glance
- Drugs Deleobuvir (Primary) ; Faldaprevir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Registrational; Therapeutic Use
- Acronyms HCVerso-1
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 04 Feb 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
- 28 May 2014 Planned End Date changed from 1 Oct 2014 to 1 Jan 2015 as reported by ClinicalTrials.gov record.
- 13 May 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Oct 2015 to 1 Oct 2014.